高瓴出手,又有千億白馬遭減持!頂流基金經理再次出手了
格隆匯10月27日丨據中國基金報,凱萊英披露三季報:高瓴又減持了。至此,高瓴已在三季度退出凱萊英、泰格醫藥、愛爾眼科3家公司的前十大流通股東名單。不過,公募三大百億規模以上基金經理卻強勢增持凱萊英。“醫藥女神”葛蘭在三季度時強勢增持凱萊英近500萬股,知名醫藥基金經理趙蓓執掌工銀瑞信前沿醫療也新進買入312萬股至第五大流通股東,廣發知名基金經理吳興武掌舵的廣發醫療保健也增持41.69萬股至250萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.